Arcutis Biotherapeutics (ARQT) Earnings Date, Estimates & Call Transcripts $10.14 -0.10 (-0.98%) (As of 11/22/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Arcutis Biotherapeutics Latest Earnings SummaryUpcoming Earnings DateFeb. 25EstimatedActual EPS (Nov. 6) -$0.33 Beat By $0.09 Consensus EPS (Nov. 6) -$0.42 Arcutis Biotherapeutics posted Q3 2024 earnings on November 6, 2024, reporting an EPS of -$0.33, which beat the consensus estimate of -$0.42 by $0.09. Quarterly revenue was reported to be $44.76 million, above analysts' expectations of $38.05 million. With a trailing EPS of -$1.79, Arcutis Biotherapeutics' earnings are expected to grow next year, from ($1.34) to ($1.07) per share. Conference Call TranscriptConference Call AudioARQT Upcoming EarningsArcutis Biotherapeutics' next earnings date is estimated for Tuesday, February 25, 2025, based off prior year's reporting schedules. Get Arcutis Biotherapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arcutis Biotherapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataARQT Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ARQT Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Arcutis Biotherapeutics Analyst EPS EstimatesCurrent Year EPS Consensus Estimate:($1.34) EPSNext Year EPS Consensus Estimate: ($1.07) EPS Arcutis Biotherapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 2/25/2025(Estimated)------- 11/6/2024--$0.42-$0.33+$0.09-$0.33$38.05M$44.76M 8/14/2024Q2 2024-$0.48-$0.42+$0.06-$0.42$31.00M$30.86M 5/14/2024Q1 2024-$0.60-$0.32+$0.28-$0.32-$49.57M 2/27/2024Q4 2023-$0.64-$0.72 -$0.08-$0.72$11.78M$13.53M 11/3/2023Q3 2023-$0.90-$0.73+$0.17-$0.73$9.54M$38.11M 8/8/2023Q2 2023-$1.22-$1.16+$0.06-$1.16$4.87M$5.19M Get the Latest News and Ratings for ARQT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. 5/9/2023Q1 2023-$1.30-$1.31 -$0.01-$1.31$3.50M$2.78M 2/28/2023Q4 2022-$1.37-$1.18+$0.19-$1.18$2.84M$2.96M Arcutis Biotherapeutics Earnings - Frequently Asked Questions When is Arcutis Biotherapeutics's earnings date? Arcutis Biotherapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based off last year's report dates. Learn more on ARQT's earnings history. Did Arcutis Biotherapeutics beat their earnings estimates last quarter? In the previous quarter, Arcutis Biotherapeutics (NASDAQ:ARQT) reported ($0.33) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.42) by $0.09. Learn more on analysts' earnings estimate vs. ARQT's actual earnings. How can I listen to Arcutis Biotherapeutics's earnings conference call? The conference call for Arcutis Biotherapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Arcutis Biotherapeutics's conference call transcript? The conference call transcript for Arcutis Biotherapeutics's latest earnings report can be read online. Read Transcript How much revenue does Arcutis Biotherapeutics generate each year? Arcutis Biotherapeutics (NASDAQ:ARQT) has a recorded annual revenue of $138.71 million. How much profit does Arcutis Biotherapeutics generate each year? Arcutis Biotherapeutics (NASDAQ:ARQT) has a recorded net income of -$262.14 million. ARQT has generated -$1.79 earnings per share over the last four quarters. What is Arcutis Biotherapeutics's EPS forecast for next year? Arcutis Biotherapeutics's earnings are expected to grow from ($1.34) per share to ($1.07) per share in the next year. ` More Earnings Resources from MarketBeat Related Companies Innoviva Earnings Results Ocular Therapeutix Earnings Results Kiniksa Pharmaceuticals Earnings Results Phathom Pharmaceuticals Earnings Results ORIC Pharmaceuticals Earnings Results Supernus Pharmaceuticals Earnings Results Nkarta Earnings Results Karyopharm Therapeutics Earnings Results BioXcel Therapeutics Earnings Results Arcellx Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings Report This Bull Market Indicator called NVDA at $116 (Ad)Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here This page (NASDAQ:ARQT) was last updated on 11/24/2024 by MarketBeat.com Staff From Our PartnersTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | Sponsored#1 Crypto of 2024Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcutis Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
